We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

For five years, insulin manufacturer Novo Nordisk agrees to cap out-of-pocket cost of its insulin treatments at $35 per month, and provide free insulin to the neediest Minnesotans.

The settlement resolves the Attorney General’s 2018 lawsuit alleging that Novo Nordisk deceptively priced its insulin.

Attorney General Keith Ellison announced a settlement with Novo Nordisk that let's Minnesotans buy its insulin products for $35 per month.

Insulin allows cells to absorb and use glucose. In people with insulin resistance, the cells are unable to use insulin effectively. Insulin resistance occurs when cells in the body do not respond ...

Novo Nordisk (NYSE:NVO) is a Denmark-based firm that owns drug brands such as Levemir, Tresiba, NovoLog, Novolin R, and Novolin N. Overall, NVO ranks 6th on our list of firms that took a hit on ...

Prices for insulin, the essential drug for treating diabetes, have plummetted to their lowest levels in a decade following a rise in generic options. Insulin prices averaged 19 cents per unit as ...

We remain the only company investing in a comprehensive ecosystem of differentiated technology for intensive insulin patients that takes on more of the work of the diabetes management and takes it off ...

Many drugs, including insulin, essentially became free. But the American Rescue Plan made a major change that hit drug companies with even larger penalties for raising prices. In January 2024 ...

Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] Gov. Gavin Newsom’s ambitious plan to produce a cheap, generic insulin for the 3.2 million Californians with diabetes is behind the ...